The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials.
|Number of pages||14|
|Journal||Journal of Medicinal Chemistry|
|State||Published - Jun 13 2019|
Bibliographical noteFunding Information:
This research was supported in part by NIH Awards U01AG043415, R01NS056051, R01AG031311, and R01NS093920 as well as ADDF Award 261108. We thank Dr. Christos D. Malliakas for his assistance with crystallographic structure and physical property studies of compound 11 and James Schavocky for his assistance and help with manuscript preparation.
© 2019 American Chemical Society.
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery